Are you Dr. Shustov?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 61 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E
# G3-200
Seattle, WA 98109Phone+1 206-288-6739Fax+1 206-288-6473- Is this information wrong?
Summary
- Dr. Andrei Shustov, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington and Pennsylvania. He is affiliated with UW Medicine/University of Washington Medical Center and is an Assistant Professor at University of Washington School of Medicine.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
- Wellspan Health/York HospitalResidency, Internal Medicine, 2000 - 2003
- Crimea State Medical UniversityClass of 1993
Certifications & Licensure
- WA State Medical License 2003 - 2026
- PA State Medical License 2000 - 2003
Clinical Trials
- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
- Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 807 citationsTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Ryan M. Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga
Nature Medicine. 2015-07-20 - 87 citationsOutcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.Victor A. Chow, Ajay K. Gopal, David G. Maloney, Cameron J. Turtle, Stephen D. Smith
American Journal of Hematology. 2019-05-21 - 45 citationsEfficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study ...Ajay K. Gopal, Oliver W. Press, Andrei R. Shustov, Stephen H. Petersdorf, Ted Gooley
Leukemia & Lymphoma. 2010-08-11
Authored Content
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
Press Mentions
- ALK-Negative Anaplastic Large Cell Lymphoma: Features and Outcomes of 235 Patients from the International T-cell ProjectJanuary 27th, 2021
- Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care AwardNovember 25th, 2019
- Characterizing the Belinostat Response in Patients with Relapsed or Refractory Angioimmunoblastic T-cell LymphomaNovember 9th, 2019
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- UW Medicine/University of Washington Medical CenterSeattle, Washington